Pharma Assay Development Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Assay Development Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Assay Development Services Today - Breaking & Trending Today

Mission Bio Launches Early Access Program for Single-Cell Measurable Residual Disease Detection in Blood Cancers

Published: July 28, 2022

/PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced the initial availability of the industry's first...

Source: prnewswire.com

Related Topics:

Aaron LlansoTodd DruleyOxford BiomedicaConsort Partners For Mission BioClinical Applications At Mission BioEarly Access ProgramMission Bio IncExchange CommissionAgilent TechnologiesMayfield FundMission Bio Pharma Assay Development ServicesMission BioMemorial Sloan Kettering Cancer CenterSingle Cell Multi OmicsSenior DirectorClinical ApplicationsChief Medical OfficerPharma Assay Development ServicesNew YorkNovo GrowthCota CapitalPrivate Securities Litigation Reform ActQuarterly ReportMinimal Residual DiseaseAcute Myeloid Leukemia

Mission Bio Launches Early Access Program for Single-Cell Measurable Residual Disease Detection in Blood Cancers

Published: July 28, 2022

Mission Bio Launches Early Access Program for Single-Cell Measurable Residual Disease Detection in Blood Cancers - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com

Related Topics:

Aaron LlansoTodd DruleyOxford BiomedicaConsort Partners For Mission BioClinical Applications At Mission BioEarly Access ProgramMission Bio IncExchange CommissionAgilent TechnologiesMayfield FundMission Bio Pharma Assay Development ServicesMission BioMemorial Sloan Kettering Cancer CenterSingle Cell Multi OmicsSenior DirectorClinical ApplicationsChief Medical OfficerPharma Assay Development ServicesNew YorkNovo GrowthCota CapitalPrivate Securities Litigation Reform ActQuarterly ReportMinimal Residual DiseaseAcute Myeloid Leukemia